VRTX Price Prediction Next Week
Analysis and Insights
News Impact:
Vertex Pharmaceuticals (VRTX) has recently received FDA approval for Journavx, a non-opioid pain medication, marking a significant milestone as the first new class of pain treatment in over 20 years. This approval is expected to drive revenue growth and strengthen VRTX's market position in the pain management sector. However, the placement of Journavx on Tier 3 by UnitedHealth may limit patient access due to higher costs.
Technical Analysis:
The stock is currently trading at $488.29 with a neutral RSI of 63.96, indicating a stable momentum. The MACD is positive at 9.85, suggesting bullish momentum, but the MACD histogram is slightly negative, signaling a potential near-term pullback. The stock is trading above its 20 and 50-day moving averages, indicating a strong uptrend.
Fibonacci Levels:
The Fibonacci levels suggest resistance at $492.45 (R1) and $497.65 (R2), with support at $475.62 (S1). The stock is currently trading near the pivot point of $484.04.
Price Prediction:
Based on the technical indicators and the positive news sentiment, VRTX is expected to trade between $485 and $492 next week. The stock is likely to test the resistance at $492.45 but may face selling pressure at this level.
Recommendation:
Buy VRTX with a target price of $492. The stock is in an uptrend, and the FDA approval of Journavx provides a positive catalyst. However, be cautious of potential resistance at $492.45 and consider taking profits at this level.
VRTX Similar Chart Price Prediction
The price of VRTX is predicted to go up 15.01%, based on the high correlation periods with POST. The similarity of these two price pattern on the periods is 96.56%.
VRTX
POST
Up: 15.01%Similarity: 96.56%
VRTX Stock Forecast & Prediction For Years 2025, 2026, 2027, 2028, 2029 and 2030
Year
VRTX Price Forecast($)
Potential Return(%)
2025
405.050
-0.510
2026
550.000
14.630
2027
550.000
14.630
2028
650.000
35.480
2029
650.000
35.480
2030
750.000
56.320
What is VRTX stock price prediction 2025 ?
What is VRTX stock price prediction 2026 ?
What is VRTX stock price prediction 2027 ?
What is VRTX stock price prediction 2028 ?
What is VRTX stock price prediction 2029 ?
What is VRTX stock price prediction 2030 ?
VRTX Revenue Forecast
VRTX EPS Forecast
VRTX FAQs
What is VRTX revenue forecast for next quarter？
What is VRTX eps forecast for next quarter？
VRTX VS S&P500
The firm's CF therapies are poised to dominate the lucrative market for the foreseeable future, based on the disease-modifying potential of the drugs, chronic use by patients, and limited competition.
Vertex's leading drug candidates were mostly discovered in-house, lending credibility to its drug-discovery technology and potential to generate additional pipeline candidates.
Vertex's combination therapies have lengthy patents, protecting the profitable cystic fibrosis portfolio from generics.
VRTX Analyst's Forecast
Whitney Ijem
Canaccord Genuity
Strong Sell → Hold
2025-02-12
Price Target
$408 → $424
Downside
-6.44%
Canaccord upgraded Vertex Pharmaceuticals to Hold from Sell with a price target of $424, up from $408.
Joon Lee
Truist Securities
Strong Buy
2025-02-11
Price Target
$460 → $520
Upside
+14.22%
Greg Harrison
Scotiabank
Hold
2025-02-11
Price Target
$433 → $450
Downside
-1.16%
